We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.14B
AUM Growth
+$264M
Cap. Flow
+$471M
Cap. Flow %
15.02%
Top 10 Hldgs %
65.37%
Holding
91
New
20
Increased
10
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$159M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$94.1M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$83.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$61.6M
5
TSVT
2seventy bio
TSVT
+$59.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$82.1M
2
STTK icon
Shattuck Labs
STTK
+$75.6M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$25.2M
4
NRIX icon
Nurix Therapeutics
NRIX
+$24.8M
5
BLUE
bluebird bio
BLUE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTS
51
CALL
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$3.95M 0.13%
+307,000
New +$3.4M
ACIU icon
52
AC Immune
ACIU
$236M
$3.71M 0.12%
749,585
-1,666
-0.2% -$9.68K
VERV
53
DELISTED
Verve Therapeutics
VERV
$3.69M 0.12%
100,000
– –
KNTE
54
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.1M 0.1%
175,000
– –
DYN icon
55
Dyne Therapeutics
DYN
$4.28B
$2.56M 0.08%
215,000
– –
MLTX icon
56
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.98M 0.06%
200,000
– –
FVAM
57
DELISTED
5:01 Acquisition Corp
FVAM
$1.97M 0.06%
200,000
– –
BLSA
58
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1.96M 0.06%
200,000
– –
EUCR
59
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$1.95M 0.06%
200,000
– –
ADVM
60
DELISTED
Adverum Biotechnologies
ADVM
$1.84M 0.06%
+104,670
New +$2.1M
ARYD
61
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.49M 0.05%
150,000
– –
PMVP icon
62
PMV Pharmaceuticals
PMVP
$58.7M
$1.16M 0.04%
50,000
– –
CRBU icon
63
Caribou Biosciences
CRBU
$148M
$1.13M 0.04%
75,000
– –
ALGS icon
64
Aligos Therapeutics
ALGS
$26.3M
$1.08M 0.03%
+3,642
New +$1.33M
RPTX
65
DELISTED
Repare Therapeutics
RPTX
$1.05M 0.03%
50,000
– –
TMPM
66
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$982K 0.03%
100,000
– –
VTVT icon
67
vTv Therapeutics
VTVT
$122M
$830K 0.03%
+20,858
New +$1.12M
GLUE icon
68
Monte Rosa Therapeutics
GLUE
$1.86B
$768K 0.02%
+37,593
New +$787K
CMAXW
69
DELISTED
CareMax, Inc. Warrant
CMAXW
$768K 0.02%
100,000
– –
BOLT icon
70
Bolt Biotherapeutics
BOLT
$7.72M
$735K 0.02%
7,500
– –
EUCRW
71
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$651K 0.02%
66,666
– –
FLACW
72
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$650K 0.02%
66,665
– –
PCVX icon
73
Vaxcyte
PCVX
$7.88B
$495K 0.02%
+20,800
New +$484K
OMEG
74
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$489K 0.02%
50,000
– –
SRZNW icon
75
Surrozen Inc Warrant
SRZNW
$75.6K
$429K 0.01%
66,665
– –
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2021 Portfolio in Review

As of Q4 2021, EcoR1 Capital held 91 positions worth $3.14B, up 9.2% from $2.87B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $471M of net new capital in Q4 2021, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Nurix Therapeutics, an estimated $24.8M trimmed.

  • EcoR1 Capital's largest Q4 2021 buy was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.
  • EcoR1 Capital added most to Protagonist Therapeutics in Q4 2021, an estimated $37.8M increase.
  • EcoR1 Capital's biggest Q4 2021 reduction was Nurix Therapeutics, cutting an estimated $24.8M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2021, selling an estimated $82.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $3.14B portfolio in Q4 2021.
  • EcoR1 Capital opened 20 new positions and closed 15 in Q4 2021.
  • EcoR1 Capital's portfolio value rose 9.2% quarter-over-quarter to $3.14B.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.